Under a sweeping new blueprint to refocus, optimize, and externalize its worldwide R&D activities, Takeda Pharmaceutical Co. Ltd. is to simplify its current network of internal sites, transfer an as yet unspecified but "significant" number of employees to new external partners, and fundamentally transform ways of working as it pursues improved focus, efficiency and appropriate capability in its operations.
Refocus, Optimize, Externalize: Takeda Overhauls Global R&D
As it reported solid underlying growth in the fiscal first quarter, Takeda has unveiled a detailed implementation program for its stated strategic intent to refocus global R&D effort on selected R&D areas, in a major overhaul that will make much wider use of external partners and affect "significant" numbers of people across the company.
